The DOI matches its Crossref record; 334 of the 334 references it cites were found in a registry or an index.
NK Cell-Based Immune Checkpoint Inhibition
Open accessAbstract
Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an important mode of treatment for cancer patients. The inhibition of immune checkpoints, which are the source of immune escape for various cancers, is one such immunotherapeutic dimension. It has mainly been aimed at T cells in the past, but NK cells are a newly emerging target. Simultaneously, the number of checkpoints identified has been increasing in recent times. In addition to the classical NK cell receptors KIRs, LIRs, and NKG2A, several other immune checkpoints have also been shown to cause dysfunction of NK cells in various cancers and chronic infections. These checkpoints include the revolutionized CTLA-4, PD-1, and recently identified B7-H3, as well as LAG-3, TIGIT & CD96, TIM-3, and the most recently acknowledged checkpoint-members of the Siglecs family (Siglec-7/9), CD200 and CD47. An interesting dimension of immune checkpoints is their candidacy for dual-checkpoint inhibition, resulting in therapeutic synergism. Furthermore, the combination of immune checkpoint inhibition with other NK cell cytotoxicity restoration strategies could also strengthen its efficacy as an antitumor therapy. Here, we have undertaken a comprehensive review of the literature to date regarding NK cell-based immune checkpoints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–334 of 334
Andreae, S., Buisson, S., & Triebel, F. (2003) · Blood · doi:10.1182/blood-2003-01-0273 · Cited by 150
Targeting sialic acid–Siglec interactions to reverse immune suppression in cancer
Adams, O. J., Stanczak, M. A., von Gunten, S., & Laubli, H. P. (2017) · Glycobiology · doi:10.1093/glycob/cwx108 · Cited by 150
Essential Roles for Dok2 and RasGAP in CD200 Receptor-Mediated Regulation of Human Myeloid Cells
Mihrshahi, R., Barclay, A. N., & Brown, M. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901531 · Cited by 148
Favier, B., LeMaoult, J., Lesport, E., & Carosella, E. D. (2009) · The FASEB Journal · doi:10.1096/fj.09-135194 · Cited by 146
Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications
Moretta, L., Montaldo, E., Vacca, P., Zotto, G. D., Moretta, F., Merli, P., Locatelli, F., & Mingari, M. C. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000365632 · Cited by 146
Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice
Golden‐Mason, L., McMahan, R. H., Strong, M., Reisdorph, R. M., Mahaffey, S. B., Palmer, B. E., Cheng, L., Kulesza, C. A., Hirashima, M., Niki, T., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01085-12 · Cited by 146
Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges
Lin, A., & Yan, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02164 · Cited by 145
McWilliams, E. M., Mele, J. M., Cheney, C. M., Timmerman, E. A., Fiazuddin, F., Strattan, E., Mo, X. M., Byrd, J. C., Muthusamy, N., & Awan, F. T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1226720 · Cited by 144
Kaur, S., Soto‐Pantoja, D. R., Stein, E. V., Liu, C., ELKAHLOUN, A. G., Pendrak, M. L., Nicolae, A., SINGH, S. P., Nie, Z., Levens, D., et al. (2013) · Scientific Reports · doi:10.1038/srep01673 · Cited by 143
Davis, Z., Vallera, D. A., Miller, J. S., & Felices, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.011 · Cited by 143
Wang, W., Guo, H., Geng, J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603464 · Cited by 140
Lemke, D., Pfenning, P., Sahm, F., Klein, A.-C., Kempf, T., Warnken, U. H., Schnölzer, M., Tudoran, R., Weller, M., Platten, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0880 · Cited by 140
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur, J., Rebmann, V., Grosse‐Wilde, H., Luboldt, H., Ruebben, H., Drexler, I., Sutter, G., Huber, C., & Seliger, B. (2003) · PubMed · Cited by 137
Uhrberg, M., Valiante, N. M., Young, N. T., Lanier, L. L., Phillips, J. H., & Parham, P. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.6.3923 · Cited by 136
Juliá, E. P., Amante, A., Pampena, M. B., Mordoh, J., & Levy, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02140 · Cited by 135
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E. M., Kwok, M., Manasanch, E. E., Bhutani, M., Tageja, N., Roschewski, M. J., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.103085 · Cited by 131
Xiao, Q., Wu, J., Wang, W.-J., Chen, S., Zheng, Y., Yu, X., Meeth, K., Sahraei, M., Bothwell, A. L. M., Chen, L., et al. (2018) · Nature Medicine · doi:10.1038/nm.4496 · Cited by 130
Liu, J., Zhang, S., Hu, Y., Yang, Z., Li, J. P., Liu, X., Deng, L., Wang, Y., Zhang, X., Jiang, T., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000122 · Cited by 127
Alvarez, I. B., Pasquinelli, V., Jurado, J. O., Abbate, E. H., Musella, R. M., de la Barrera, S., & García, V. (2010) · The Journal of Infectious Diseases · doi:10.1086/654932 · Cited by 126
CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells
Kaur, S., Chang, T., SINGH, S. P., Lim, L., Mannan, P., Garfield, S. H., Pendrak, M. L., Soto‐Pantoja, D. R., Rosenberg, A. Z., Jin, S., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303116 · Cited by 126
Features of Memory-Like and PD-1+ Human NK Cell Subsets
Chiesa, M. D., Pesce, S., Muccio, L., Carlomagno, S., Sivori, S., Moretta, A., & Marcenaro, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00351 · Cited by 125
Zhou, X., Li, W., Wu, Y., Han, L., Cao, X., Yang, X.-M., Wang, H., Zhao, W., Zhai, W., Qi, Y., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02821 · Cited by 125
Self-citationThe inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes
Rijkers, E. S. K., Ruiter, T. E.-D., Baridi, A., Veninga, H., Hoek, R. M., & Meyaard, L. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.07.013 · Cited by 124
The CD4-like molecule LAG-3, biology and therapeutic applications
Sierro, S. R., Romero, P. J., & Speiser, D. E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712598.2011.540563 · Cited by 121
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Chiossone, L., Vienne, M., Kerdiles, Y. M., & Vivier, É. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.003 · Cited by 121
Wiesmayr, S., Webber, S. A., Macedo, C., Popescu, I., Smith, L., Luce, J., & Metes, D. (2011) · European Journal of Immunology · doi:10.1002/eji.201141832 · Cited by 118
CD200: A putative therapeutic target in cancer
Moreaux, J., Veyrune, J. L., Reme, T. X., Vos, J. D., & Klein, B. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.103 · Cited by 118
PD-1 Expression on Natural Killer Cells and CD8 + T Cells During Chronic HIV-1 Infection
Norris, S., Coleman, A., Kuri-Cervantes, L., Bower, M., Nelson, M. R., & Goodier, M. R. (2012) · Viral Immunology · doi:10.1089/vim.2011.0096 · Cited by 117
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita∥, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3379 · Cited by 117
Bossard, C., Bezieau, S., Matysiak‐Budnik, T., Volteau, C., LABOISSE, C. L., Jotereau, F., & Mosnier, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26453 · Cited by 116
The Dual Role of HLA-G in Cancer
Rouas‐Freiss, N., Moreau, P., LeMaoult, J., & Carosella, E. D. (2014) · Journal of Immunology Research · doi:10.1155/2014/359748 · Cited by 116
Golden‐Mason, L., Klarquist, J. S., Wahed, A. S., & Rosen, H. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3637 · Cited by 112
Gao, Q., Chen, K., Gao, L., Zheng, Y., & Yang, Y.-G. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.155 · Cited by 110
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Huang, B. Y., Zhan, Y. P., Zong, W. J., Yu, C. J., Li, J., Qu, Y. M., & Han, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134715 · Cited by 110
Bottino, C., Biassoni, R., Millo, R., Moretta, L., & Moretta, A. (2000) · Human Immunology · doi:10.1016/s0198-8859(99)00162-7 · Cited by 108
Reversal of natural killer cell exhaustion by TIM-3 blockade
Gallois, A., da Silva, I. P., Osman, I., & Bhardwaj, N. (2014) · OncoImmunology · doi:10.4161/21624011.2014.946365 · Cited by 108
Powderly, J. D., Cote, G. M., Flaherty, K. T., Szmulewitz, R. Z., Ribas, A., Weber, J. S., Loo, D. T., Baughman, J. E., Chen, F., Moore, P. A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o8 · Cited by 107
Siva, A. C., Xin, H., Qin, F., Oltean, D. I., Bowdish, K. S., & Kretz-Rommel, A. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0429-6 · Cited by 104
Demeure, C. E., Wolfers, J., Martin‐Garcia, N., Gaulard, P., & Triebel, F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00184-8 · Cited by 104
Deuss, F. A., Gully, B. S., Rossjohn, J., & Berry, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786483 · Cited by 104
NK Cell Triggering by the Human Costimulatory Molecules CD80 and CD86
Wilson, J. L., Charo, J., Martin‐Fontecha, A., Dellabona, P., Casorati, G., Chambers, B. J., Kiessling, R. W., Bejarano, M.-T., & Ljunggren, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4207 · Cited by 103
The genetic and evolutionary balances in human NK cell receptor diversity
Parham, P. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.10.002 · Cited by 102
MICA triggering signal for NK cell tumor lysis is counteracted by HLA‐G1‐mediated inhibitory signal
Menier, C., Riteau, B., Carosella, E. D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10460 · Cited by 102
T cell regulation of natural killer cells
Kerdiles, Y. M., Ugolini, S., & Vivier, É. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130960 · Cited by 102
Kim, M. J., Lee, J.-C., Lee, J., Kim, S., Lee, S. G., Park, S., Sung, M. W., & Heo, D. S. (2008) · Tumor Biology · doi:10.1159/000132568 · Cited by 101
HLA-G expression in human ovarian carcinoma counteracts NK cell function
Lin, A., Yan, W., Xu, H., Gan, M. F., Cai, J., Zhu, M., & Zhou, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm356 · Cited by 101
Shaping of NK Cell Responses by the Tumor Microenvironment
Stojanovic, A., Correia, M. P., & Cerwenka, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0125-8 · Cited by 98
Godal, R., Bachanová, V., Gleason, M., McCullar, V., Yun, G. H., Cooley, S., Verneris, M. R., McGlave, P. B., & Miller, J. S. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.01.019 · Cited by 97
Reduction of sialic acid O-acetylation in human colonic mucins in the adenoma-carcinoma sequence
Corfield, A. P., Myerscough, N., Warren, B. F., Durdey, P., Paraskeva, C., & Schauer, R. (1999) · Glycoconjugate Journal · doi:10.1023/a:1007026314792 · Cited by 95
LAG-3 does not define a specific mode of natural killing in human
Huard, B., Tournier, M., & Triebel, F. (1998) · Immunology Letters · doi:10.1016/s0165-2478(97)00170-3 · Cited by 95
The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor
Borrego, F., Masilamani, M., Kabát, J., Sanni, T. B., & Coligan, J. E. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.031 · Cited by 93
Sun, J., Yang, M., Ban, Y., Gao, W., Song, B., Wang, Y., Zhang, Y., Shao, Q., Kong, B., & Qu, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147186 · Cited by 92
Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 92
PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
Mariotti, F. R., Petrini, S., Ingegnere, T., Tumino, N., Besi, F., Scordamaglia, F., Munari, E., Pesce, S., Marcenaro, E., Moretta, A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1557030 · Cited by 92
Aberrant human leucocyte antigen‐G expression and its clinical relevance in hepatocellular carcinoma
Lin, A., Chen, H. ‐., Zhu, C., Zhang, X., Xu, H., Zhang, J. ‐., Wang, Q., Zhou, W., & Yan, W. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00917.x · Cited by 91
CD200R signaling in tumor tolerance and inflammation: A tricky balance
Rygiel, T. P., & Meyaard, L. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.002 · Cited by 88
Tomkowicz, B. E., Walsh, E. S., Cotty, A., Verona, R. I., Chi-Sabins, N., Kaplan, F. M., Santulli-Marotto, S., Chin, C., Mooney, J. M., Lingham, R. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140694 · Cited by 88
Poliovirus Receptor: More than a simple viral receptor
Bowers, J. R., Readler, J. M., Sharma, P., & Excoffon, K. J. D. A. (2017) · Virus Research · doi:10.1016/j.virusres.2017.09.001 · Cited by 87
Křen, L., Slabý, O., Múčková, K., Lžičařová, E., Sova, M., Vybíhal, V., Svoboda, T., Fadrus, P., Lakomý, R., Vaňhara, P., et al. (2010) · Neuropathology · doi:10.1111/j.1440-1789.2010.01149.x · Cited by 84
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Wang, Z., Zhu, J., Gu, H., Yuan, Y., Zhang, B., Zhu, D., Zhou, J., Zhu, Y., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1052145 · Cited by 84
Geldhof, A. B., Moser, M., Lespagnard, L., Thielemans, K., & BAETSELIER, P. D. (1998) · Blood · doi:10.1182/blood.v91.1.196 · Cited by 83
Alblas, J., Honing, H., de Lavalette, C. R., Brown, M. H., Dijkstra, C. D., & van den Berg, T. K. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7181-7192.2005 · Cited by 82
Inoue, S., Lin, S., Chang, T., Wu, S., Yao, C., Chu, T., Troy, F. A., & Inoue, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27199 · Cited by 82
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Lian, S., Xie, R., Ye, Y., Lu, Y., Cheng, Y., Xie, X., Li, S., & Jia, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-40241-1 · Cited by 81
Avril, T., North, S. J., Haslam, S. M., Willison, H. J., & Crocker, P. R. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1005559 · Cited by 81
Stumpfova, M., Ratner, D., Desciak, E. B., Eliezri, Y. D., & Owens, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4380 · Cited by 80
Rygiel, T. P., Karnam, G., Goverse, G., van der Marel, A. P. J., Greuter, M., van Schaarenburg, R. A., Visser, W. F., Brenkman, A. B., Molenaar, R., Hoek, R. M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.477 · Cited by 80
Kareva, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102134 · Cited by 80
Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials
Suen, C.-W. W., Lee, W., Leung, K. T., Pan, X., & Li, G. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1515315 · Cited by 80
Tyrosine Phosphatase SHP-2 Binding to CTLA-4: Absence of Direct YVKM/YFIP Motif Recognition
Schneider, H., & Rudd, C. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2234 · Cited by 78
Morandi, F., Ferretti, E., Castriconi, R., Dondero, A., Petretto, A., Bottino, C., & Pistoia, V. (2011) · Blood · doi:10.1182/blood-2011-05-352393 · Cited by 77
Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction
Naji, A., Menier, C., Maki, G., Carosella, E. D., & Rouas‐Freiss, N. (2012) · Leukemia · doi:10.1038/leu.2012.62 · Cited by 76
Vitale, M., Cantoni, C., Chiesa, M. D., Ferlazzo, G., Carlomagno, S., Pende, D., Falco, M., Pessino, A., Muccio, L., Maria, A. D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01415 · Cited by 76
Hicks, K. C., Fantini, M. C., Donahue, R. N., Schwab, A., Knudson, K. M., Tritsch, S. R., Jochéms, C., Clavijo, P. E., Allen, C. T., Hodge, J. W., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466018 · Cited by 73
Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer
Peng, Y., Xi, C., Zhu, Y., Yin, L., Wei, J., Zhang, J., Liu, X., Guo, S., Fu, Y., & Miao, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11953 · Cited by 71
Tallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 71
Audenaerde, J. R. M. V., Waele, J. D., Marcq, E., Loenhout, J. V., Lion, E., den Bergh, J. M. J. V., Jesenofsky, R., Masamune, A., Roeyen, G., Pauwels, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18185 · Cited by 71
Tumor immunotherapy: New aspects of natural killer cells
Li, Y., & Sun, R. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.02 · Cited by 71
Brignone, C., Grygar, C., Marcu, M., Schäkel, K., & Triebel, F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4202 · Cited by 70
Liu, F., Zeng, G., Zhou, S., He, X., Sun, N., Zhu, X., & Hu, A. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.01.018 · Cited by 70
Nath, P. R., Gangaplara, A., Pal-Nath, D., Mandal, A., Maric, D., Sipes, J. M., Cam, M., Shevach, E. M., & Roberts, D. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02985 · Cited by 69
Kohlhapp, F. J., Broucek, J. R., Hughes, T. M., Huelsmann, E. J., Lusciks, J., Zayas, J. P., Dolubizno, H., Fleetwood, V. A., Grin, A., Hill, G. R., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0063-3 · Cited by 68
Parham, P. (2004) · Immunology Letters · doi:10.1016/j.imlet.2003.11.016 · Cited by 68
Levy, E. M., Sycz, G., Arriaga, J. M., Barrio, M. M., von Euw, E. M., Morales, S. B., Gonzalez, M. S., Mordoh, J., & Bianchini, M. (2009) · Innate Immunity · doi:10.1177/1753425908101404 · Cited by 66
Lin, A., Zhu, C., Chen, H. ‐., Chen, B. ‐., Zhang, X., Zhang, J. ‐., Wang, Q., Zhou, W., Hu, W., Yang, H., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00858.x · Cited by 65
O‐acetylation and de‐O‐acetylation of sialic acids in human colorectal carcinoma
Shen, Y., Kohla, G., Lrhorfi, L. A., Sipos, B., Kalthoff, H., Gerwig, G. J., Kamerling, J. P., Schauer, R., & Tiralongo, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03927.x · Cited by 63
Kelly, J. M., Takeda, K., Darcy, P. K., Yagita∥, H., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4472 · Cited by 62
Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice
Gorczynski, R. M., Chen, Z., Diao, J., Khatri, I. A., Wong, K. K. W., Yu, K., & Behnke, J. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0667-8 · Cited by 62
Jost, S., Moreno‐Nieves, U. Y., García-Beltrán, W. F., Rands, K., Reardon, J., Tóth, I., Trocha, A. K., Altfeld, M. A., & Addo, M. M. (2013) · Retrovirology · doi:10.1186/1742-4690-10-74 · Cited by 62
B7-H3 Overexpression Predicts Poor Survival of Cancer Patients: A Meta-Analysis
Ye, Z., Zheng, Z., Li, X., Zhu, Y., Zhong, Z.-P., Peng, L., & Wu, Y. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447859 · Cited by 62
Pierson, B., Gupta, K., Hu, W.-S., & Miller, J. S. (1996) · Blood · doi:10.1182/blood.v87.1.180.bloodjournal871180 · Cited by 61
Wan, R., Wang, Z., Li, H., Peng, X., Liu, G., Ou, J.-M., & Cheng, A. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485819 · Cited by 61
TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells
Folgiero, V., Cifaldi, L., Pira, G. L., Goffredo, B. M., Vinti, L., & Locatelli, F. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0134-4 · Cited by 60
Lanuza, P. M., Vigueras, A., Oliván, S., Prats, A., Costas, S., Llamazares, G. A., Sánchez‐Martínez, D., Ayuso, J. M., Fernández, L. J., Ochoa, I., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395123 · Cited by 60
Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1
Assal, A., Kaner, J. D., Pendurti, G., & Zang, X. (2015) · Immunotherapy · doi:10.2217/imt.15.78 · Cited by 58
Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation
Zhang, S., & Phillips, J. H. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705398 · Cited by 56
Brunetti, L., Noto, R. D., Abate, G., Gorrese, M., Gravetti, A., Raia, M., Scalia, G., Pascariello, C., Camera, A., & Vecchio, L. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07644.x · Cited by 55
Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155
Deuss, F. A., Watson, G. M., Fu, Z., Rossjohn, J., & Berry, R. (2018) · Structure · doi:10.1016/j.str.2018.10.023 · Cited by 53
Komita, H., Koido, S., Hayashi, K., Kan, S., Ito, M., Kamata, Y., Suzuki, M., & Homma, S. (2015) · Oncology Reports · doi:10.3892/or.2015.4149 · Cited by 52
Villa-Álvarez, M., Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Páyer, Á. R., González-García, E., Villa-Álvarez, M. C., López‐Soto, A., & Gonzalez, S. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02917 · Cited by 50
Role of the CTLA-4 receptor in t cell activation and immunity
Scheipers, P., & Reiser, H. (1998) · Immunologic Research · doi:10.1007/bf02788753 · Cited by 48
Wang, F., Xie, B., Wang, B., & Troy, F. A. (2015) · Glycobiology · doi:10.1093/glycob/cwv051 · Cited by 47
Inhibitory leukocyte immunoglobulin-like receptors in cancer development
Zhang, F., Zheng, J., Kang, X., Deng, M., Lu, Z., Kim, J., & Zhang, C. C. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4925-1 · Cited by 46
TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy
Liu, X., Hou, M., & Liu, Y. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1237524 · Cited by 46
Segal, N. H., Naidoo, J., Curigliano, G., Patel, S. P., Sahebjam, S., Papadopoulos, K. P., Gordon, M. S., Wang, D., Rueda, A. G., Song, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3540 · Cited by 46
A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma
Liu, J.-Q., Talebian, F., Wu, L., Li, M., Li, M.-S., Wu, L., Zhu, J., Markowitz, J., Carson, W. E., Basu, S., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600052 · Cited by 45
Juno, J. A., Stalker, A., Waruk, J. L. M., Oyugi, J. O., Kimani, M., Plummer, F. A., Kimani, J., & Fowke, K. R. (2015) · Retrovirology · doi:10.1186/s12977-015-0142-z · Cited by 44
B7-H3 and its relevance in cancer immunological and non-immunological perspectives
Nygren, M. K. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e304 · Cited by 43
Byun, H., Jung, W., Lee, D., Kim, S., Kim, S. J., Park, C., Chung, H. Y., & Chun, T. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.002 · Cited by 42
Stamm, H., Wellbrock, J., & Fiedler, W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9770-7 · Cited by 42
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome
Yalniz, F., Daver, N. G., Rezvani, K., Kornblau, S. M., Ohanian, M. N., Borthakur, G. M., Dinardo, C. D., Konopleva, M. Y., Burger, J. A., Gasior, Y., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.011 · Cited by 41
Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
Li, W., Blessin, N. C., Simon, R., Kluth, M., Fischer, K., Hube‐Magg, C., Makrypidi‐Fraune, G., Wellge, B., Mandelkow, T., Debatin, N. F., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5111-1 · Cited by 41
Hattori, N., Kawaguchi, Y., Sasaki, Y., Shimada, S., Murai, S., Abe, M., Baba, Y., Watanuki, M., Fujiwara, S., Arai, N., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.013 · Cited by 41
Linedale, R., Schmidt, C., King, B., Ganko, A. G., Simpson, F., Panizza, B. J., & Leggatt, G. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175755 · Cited by 40
Vey, N., Dumas, P., Récher, C., Gastaud, L., Lioure, B., Bulabois, C., Pautas, C., Marolleau, J., Leprêtre, S., Raffoux, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.889.889 · Cited by 40
Immune Checkpoint Blockade across the Cancer Care Continuum
Helmink, B. A., Gaudreau, P.-O., & Wargo, J. A. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.003 · Cited by 39
Tim-3 Negatively Mediates Natural Killer Cell Function in LPS-Induced Endotoxic Shock
Hou, H., Liu, W., Wu, S., Lu, Y., Peng, J., Zhu, Y., Lu, Y., Wang, F., & Ziyong, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110585 · Cited by 38
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Weng, T., Huang, S.-S., Yen, M., Lin, C., Chen, Y., Lin, C.-M., Chen, W.-C., Wang, C., Chang, J., & Lai, M.-D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.236 · Cited by 35
Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
Kosmaczewska, A., Ciszak, L., Boćko, D., & Frydecka, I. (2001) · PubMed · Cited by 35
Leveraging Natural Killer Cells for Cancer Immunotherapy
Grossenbacher, S. K., Aguilar, E. G., & Murphy, W. J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0013 · Cited by 33
Hong, X., Wang, X., Wang, T., et al. (2018) · Medical Science Monitor · doi:10.12659/msm.910388 · Cited by 30
Fuchs, A. G., & Colonna, M. (2011) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.1.2011.4.1 · Cited by 27
Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
Heidenreich, S., zu Eulenburg, C., Hildebrandt, Y., Stübig, T., Sierich, H., Badbaran, A., EIERMANN, T. H., Binder, T. M. C., & Kröger, N. M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/652130 · Cited by 27
Kritikou, J. S., Dahlberg, C. I. M., Baptista, M. A. P., Wagner, A. K., Banerjee, P. P., Gwalani, L. A., Poli, M. C., Panda, S. K., Kärre, K., Kaech, S. M., et al. (2016) · Scientific Reports · doi:10.1038/srep30636 · Cited by 27
Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy
Zingoni, A., Vulpis, E., Nardone, I., Soriani, A., Fionda, C., Cippitelli, M., & Santoni, A. (2016) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2017020166 · Cited by 27
Characterisation of Bovine Leukocyte Ig-like Receptors
Hogan, L. E., Bhuju, S., Jones, D. C., Laing, K. G., Trowsdale, J., Butcher, P. D., Singh, M., Vordermeier, M. H., & Allen, R. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034291 · Cited by 23
Huang, C.-H., Liao, Y., Fan, T., Chiou, T.-J., Lin, Y.-H., & Twu, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041073 · Cited by 22
DeSantes, K. B., Maris, J. M., McDowell, K. A., Mackall, C. L., Shankar, S. M., Vasselli, J., Chen, F., Loo, D. T., Moore, P. A., Wigginton, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps2596 · Cited by 21
Ager, C. R., Reilley, M. J., Nicholas, C., Bartkowiak, T., Jaiswal, A. R., Curran, M. A., Albershardt, T. C., Bajaj, A., Archer, J. F., Reeves, R. S., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0173-6 · Cited by 17
Rexin, P., Tauchert, A., Hänze, J., Heers, H., Schmidt, A., Hofmann, R. W., & Hegele, A. (2018) · Anticancer Research · doi:10.21873/anticanres.12517 · Cited by 15
Ji, P., Chen, D., Bian, J., Xia, R., Song, X., Wen, W., Zhang, X., & Zhu, Y. (2015) · 细胞与分子免疫学杂志 · Cited by 10
Atfy, M., Ebian, H. F., & Elshorbagy, S. M. (2015) · Journal of Leukemia · doi:10.4172/2329-6917.1000190 · Cited by 10
NK/DC crosstalk in immunosurveillance: A broken relationship caused by WASP‐deficiency
Romagnani, C., & Babić, M. (2014) · European Journal of Immunology · doi:10.1002/eji.201444514 · Cited by 6
Nobel goes to immune checkpoint—Innovative cancer treatment by immunotherapy
Li, J., & Dong, C. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9409-7 · Cited by 3
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
Wang, M., Krueger, J. B., Gilkey, A. K., Stelljes, E. M., Kluesner, M. G., Pomeroy, E. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., Claudio Vázquez, P. N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009560 · Cited by 45
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
Metadata
- Authors
- Khan, M., Arooj, S., & Wang, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-13
- Volume
- 11
- Pages
- 167-167
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3006483160
- Cited by
- 356
- References
- 334
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.